Stryker acquires Inari Medical for $4.9B
Stryker, a global medtech company based out of Michigan, has kicked off 2025 with a bit of excitement, agreeing to acquire Inari Medical for a whopping $4.9 billion.
California-based Inari was founded in 2011. The company is known globally for its advanced technologies designed to improve outcomes for patients with pulmonary embolism, deep vein thrombosis and other significant vascular conditions. Its devices are sold in more than 30 countries all over the world, and its revenue in 2024 was estimated to be approximately $603 million.
According to Stryker, Inari’s peripheral vascular portfolio is highly complementary to its own neurovascular offerings. The company also sees this move as a signal that its own role as a leader in endovascular health is continuing to climb.
“The acquisition of Inari expands Stryker's portfolio to provide life-saving solutions to patients who suffer from peripheral vascular diseases,” Kevin Lobo, chair and CEO of Stryker, said in a statement. “These innovations elevate the standard of care for venous thromboembolism patients and will accelerate Stryker’s impact in endovascular procedures.”
“Inari has positively impacted the lives of hundreds of thousands of patients through the development of purpose-built tools that address unmet patient needs,” added Drew Hykes, CEO of Inari. “With Stryker’s capabilities and global infrastructure, we will be even better positioned to accelerate the development of innovative new solutions and expand our footprint.”
Stryker and Inari’s boards of directors have already unanimously approved this transaction; it is expected to close in Q1 2025.
Stryker has made M&A deals a top priority in recent months, agreeing to acquire both Vertos Medical and care.ai in August 2024. The financial details of those transactions were not made public.
Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.